First-in-Class Ocular Drug Delivery System
With over than 600 million patients worldwide , intravitreal injection is currently one of the most common treatment practice for a wide range of retinal diseases.
Opharmic’s first product, the MeticTouch, is designed with a specific focus on safety, non-invasiveness, and effectiveness in delivering therapeutics for anterior and posterior eye diseases treatment.
 World Report on Vision, World Health Organisation, 2019
Opharmic's MeticTouch system offers non-invasive and effective ocular treatments with targeted drug delivery.
Highly reducing patient discomfort and fear as well as eliminating risks of procedural and post-operative complications, Opharmic's treatment procedure saves up to 80% of time needed in drug administration in comparison to the conventional eye injection.
Based on over a decade of research, safety, efficacy, and drug bioavailability of the patented technology behind the system is well-demonstrated in preclinical studies.